Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma